AGENT CAPITAL
AGENT CAPITAL
Social Links:
Industry:
Venture Capital
Founded:
2017-01-01
Status:
Active
Contact:
844-691-6233
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics Google Tag Manager WordPress Content Delivery Network Google Universal Analytics
Similar Organizations
1843 Capital
Early stage, technology venture capital fund
3737 North Capital
A technology driven Venture Capital firm.
3x5 Partners
3x5 Partners is a growth-oriented venture capital firm.
Iaso Ventures
Early-stage healthcare venture capital firm
SR One
SR One is the corporate venture capital arm of GlaxoSmithKline.
Techstars Corporate Partner
A venture-capital branch of Techstars.
Walden International
Walden International is a venture capital firm.
WelCan Capital
A cannabis-focused venture firm.
Current Employees Featured
Geeta Vemuri
Geeta Vemuri Co-Founder & Managing Partner @ Agent Capital Co-Founder & Managing Partner 2017-01-01
Preston Noon
Preston Noon Co-Founder & General Partner @ Agent Capital Co-Founder & General Partner
Founder
Geeta Vemuri
Preston Noon
Investments List
Date | Company | Article | Money raised |
---|---|---|---|
2022-06-21 | Carbon Biosciences | Agent Capital investment in Series A - Carbon Biosciences | 38 M USD |
2022-06-13 | ImCheck Therapeutics | Agent Capital investment in Series C - ImCheck Therapeutics | 96 M EUR |
2022-06-07 | Vittoria Biotherapeutics | Agent Capital investment in Seed Round - Vittoria Biotherapeutics | 10 M USD |
2022-03-22 | Affini-T Therapeutics | Agent Capital investment in Venture Round - Affini-T Therapeutics | 175 M USD |
2021-12-06 | Cyrus Biotechnology | Agent Capital investment in Series B - Cyrus Biotechnology | 18 M USD |
2021-08-18 | Immunitas Therapeutics | Agent Capital investment in Series B - Immunitas Therapeutics | 58 M USD |
2021-05-18 | Interius BioTherapeutics | Agent Capital investment in Series A - Interius BioTherapeutics | 76 M USD |
2021-03-31 | Entrada Therapeutics | Agent Capital investment in Series B - Entrada Therapeutics | 116 M USD |
2021-03-30 | Pyxis Oncology | Agent Capital investment in Series B - Pyxis Oncology | 152 M USD |
2021-03-17 | Mediar Therapeutics | Agent Capital investment in Seed Round - Mediar Therapeutics | N/A |